News and Press Releases
Eisai Named on TIME100 Most Influential Companies 2024 List
3 June 2024 -- Tokyo, Japan -- Eisai Co announced today that TIME has selected Eisai as one of the TIME100 Most Influential Companies of 2024. TIME reveals the TIME100...
Category: Biotechnology, Other
Posted: June 3, 2024
SolasCure Selected for Innovate UK Global Incubator Programme in Houston
Programme delivered in partnership with the Texas Medical Centre Programme will support Aurase Wound Gel for future entry into US market, advancing SolasCure’s mission to transform chronic wound care for...
Category: Biotechnology, Other
Posted: June 3, 2024
Michael McSorley appointed as new managing director of Origin
3 June 2024 -- Melton, UK -- Global pharmaceutical solutions provider, Origin, has today appointed Michael McSorley as new managing director. Michael McSorley With almost a decade’s experience in the...
Category: Logistics, Manufacturing and Packing
Posted: June 3, 2024
DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation
3 June 2024 -- Cambridge and Newcastle, UK -- DefiniGEN and Atelerix today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma...
Category: Drug Delivery, Logistics, Pharmaceutical
Posted: June 3, 2024
DefiniGEN Ltd, Babraham Research Campus, Maia Building, Babraham, Cambridge, CB22 3AT, United Kingdom
Bionova Scientific announces plans for new Plasmid DNA GMP facility
Facility in The Woodlands, Texas, US, to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025 3 June 2024 -- California, US --...
Category: BioManufacturing, Manufacturing and Packing, Pharmaceutical
Posted: June 3, 2024
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Ardena appoints Jeremie Trochu as Chief Executive Officer
3 June 2024 -- Ghent, Belgium -- Ardena today announces the retirement of Harry Christiaens PhD, and the subsequent appointment of Jeremie Trochu as chief executive officer. Jeremie is a...
Category: BioManufacturing, Biotechnology, Logistics, Manufacturing and Packing, Pharmaceutical
Posted: June 3, 2024
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting
2 June 2024 -- Utrecht, The Netherlands and Massachusetts, US -- Merus NV, a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced updated interim clinical...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 2, 2024
Johnson & Johnson submits application to the European Medicines Agency seeking approval of subcutaneous formulation of RYBREVANT▼ (amivantamab) for the treatment of patients with EGFR-mutated non-small cell lung cancer
Submission is supported by data from the phase 3 PALOMA-3 study featured at the American Society of Clinical Oncology (ASCO) Annual Meeting New formulation showed non-inferiority to intravenous administration in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 31, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
RYBREVANT▼ (amivantamab) plus lazertinib shows longer progression-free survival versus osimertinib in the first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
Investigational chemotherapy-free regimen of amivantamab plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease Landmark phase 3 MARIPOSA data featured in an oral...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 31, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Enveric Biosciences to Participate in BIO International Convention 2024
30 May 2024 -- Massachusetts, US -- Enveric Biosciences, a biotechnology company dedicated to the development of novel neuroplastogenic small molecule therapeutics for the treatment of depression, anxiety and addiction disorders,...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: May 30, 2024
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
Sparking change for women’s health: 11 promising femtech start-ups descend on Discovery Park, kicking off 2024 business support programme
The Femtech & Women’s Health edition of ‘Discovery Spark’ champions early stage businesses working to close the gender health gap 30 May 2024 -- Kent, UK -- Discovery Park, Kent’s...
Category: Biotechnology, Pharmaceutical
Posted: May 30, 2024
New CAS BioFinder Discovery Platform empowers drug discovery scientists to reveal insights, drive innovation and save time
Transformative new scientific information capabilities combine an unparalleled collection of curated science data with advanced predictive models to accelerate early-stage drug discovery innovation 21 May 2024 – Columbus, OH, US...
Category: Drug Discovery
Posted: May 30, 2024
Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024
